Last updated: 2026-10-13 19:18:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
SL Science Holding Limited (SLBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.52, with a market capitalisation of $846.75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.42 to $14.50. This page covers its latest market performance, valuation, price trends and company information.
$846.75M | |
$1.49 | |
$53.95 | |
$1.42 | |
$1.51 | |
90.84K | |
79.45K | |
-- | |
$14.50 | |
$1.42 | |
-- | |
-- |
SL Science Holding Limited (SLBT) is currently trading at $1.52 as of 2026-10-13 19:17:00, up 0.66% ($0.01) from the previous close of $1.51
During today's regular trading session, SLBT has traded between $1.42 and $53.95, with a trading volume of 90.84K shares. The current price is near the lower end of today's range.
Over the past seven days, SL Science Holding Limited (SLBT) moved from $1.57 to $1.52, representing a decline of 3.18% ($0.05).
The stock traded between $1.47 and $1.75 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 48.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.8%
SLBT is currently trading at $1.52, placing it 0.8% of the way from its 52-week low of $1.42 to its 52-week high of $14.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SL Science Holding Limited (SLBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.